Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543326 | 0.90 | POLB (0.55) | NAAAPOLBMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL15887755 | 0.90 | NAAA (0.56) | NAAASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL29886403 | 0.90 | POLB (0.55) | NAAAPOLBMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL5657596 | 0.87 | POLB (0.65) | POLBMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14289184 | 0.87 | POLB (0.55) | POLBMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11038520 | 0.85 | NAAA (0.72) | NAAAPOLBMAPK1ALDH1A1KDM4E | |
| SCHEMBL5655974 | 0.85 | NAAA (0.72) | NAAAPOLBMAPK1ALDH1A1KDM4E | |
| SCHEMBL13593371 | 0.85 | NAMPT (0.62) | POLBMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15390317 | 0.84 | NPC1 (0.53) | POLBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL4957518 | 0.84 | PPARG (0.59) | MAPK1SMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296599-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2016-10-13 | — | — | US | claimed |
| US-8975227-B2 | Intraoral dosage forms of glucagon | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-03-10 | — | — | US | claimed |
| EP-1791553-B1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | EMISPHERE TECH INC (US) | 2013-10-23 | — | — | EP | claimed |
| US-20110183898-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AG0NISTS | EMISPHERE TECHNOLOGIES INC. (NY) | 2011-07-28 | — | — | US | claimed |
| US-20080207514-A1 | Drug delivery agents of N-([2-hydroxybenzoyl- or 2-hydroxynaphthoyl]-amino)alkanoic acid derivatives or salts; phenoxyalkanoic acid or salts; increased bioavailability; hyperglycemic agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-08-28 | — | — | US | claimed |
| EP-1791553-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | Emisphere Technologies, Inc. (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2007011958-A2 | INTRAORAL DOSAGE FORMS OF GLUCAGON | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2006017251-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050009748-A1 | Compositions for delivering peptide YY and PYY agonists | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-01-13 | — | — | US | claimed |
| WO-2024118480-A1 | USE OF ANTIVIRAL AGENTS, COMPOSITION OF MATTER, COMBINATION PREPARATIONS/AGENTS TO TREAT CHRONIC DISEASES ASSOCIATED WITH EPSTEIN-BARR VIRUS AND OTHER HUMAN HERPES VIRUSES | EPIPHANY BIOSCIENCES (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20180338923-A1 | FORMULATIONS FOR DELIVERING INSULIN | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-9498487-B2 | Topical cromolyn formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| WO-2006017251-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1624882-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | Emisphere Technologies, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005112943-A1 | TOPICAL CROMOLYN FORMULATIONS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005112937-A1 | ACYCLOVIR FORMULATIONS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050009748-A1 | Compositions for delivering peptide YY and PYY agonists | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004104018-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183898-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AG0NISTS | GIPR, NPY1R, GLP1R | NAAA 2619/4885POLB 4833/4885MAPK1 3693/4885 |
| US-20080207514-A1 | Drug delivery agents of N-([2-hydroxybenzoyl- or 2-hydroxynaphthoyl]-amino)alkanoic acid derivatives or salts; phenoxyalkanoic acid or salts; increased bioavailability; hyperglycemic agents | GLP1R, SLC5A2, IAPP | NAAA 372/4885POLB 4600/4885MAPK1 2637/4885 |
| US-20050009748-A1 | Compositions for delivering peptide YY and PYY agonists | NPY1R, NPY4R, NPY2R | NAAA 2909/4885POLB 4679/4885MAPK1 3001/4885 |
| US-20180338923-A1 | FORMULATIONS FOR DELIVERING INSULIN | IAPP, INSR, IRS1 | NAAA 3346/4885POLB 3718/4885MAPK1 2935/4885 |
| US-20160296599-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | NPY1R, NPY4R, NPY2R | NAAA 2839/4885POLB 4676/4885MAPK1 2971/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | NAAA 3559/4885POLB 2682/4885MAPK1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.